Report: Predictive Genetic Testing Market to Reach $4.6B by 2025 | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Report: Predictive Genetic Testing Market to Reach $4.6B by 2025

March 6, 2017
by Rajiv Leventhal
| Reprints

The global predictive genetic testing and consumer/wellness genomics market is anticipated to reach $4.6 billion by 2025, according to a report from Research and Markets.

According to the report, key drivers attributing to the market expansion include rising awareness pertaining to the use of genomic tests for the prediction of gene susceptibility for probability of disease development. Genetic data in the ecosystem increases when consumers buy direct-to-consumer genomics products or participate in clinical research trials.

Rising encouragement for the use of these products is anticipated to propel industrial growth. Expansion in the range of consumer genetic tests by market entities is anticipated to fuel progress in the market in the coming years. Introduction of novel platforms anticipates the DNA-powered applications thus rising market penetration.

Moreover, according to the research, the pharmaceutical companies are also engaged in partnerships with genomics companies in order to develop novel therapeutics on the basis of genotypic and phenotypic correlations. For instance, in April 2016 a 10-year deal was signed between Human Longevity Inc. (HLI) and AstraZeneca, in which HLI is supposed to sequence 500,000 genomes of the clinical trial population of AstraZeneca. This data is to be used for the identification of novel drug targets. The deal also provides AstraZeneca with access to the proprietary knowledgebase in order augment biomarker discovery, and facilitate drug development.

Further noteworthy findings from the study include:

  • Application of genetic susceptibility tests in gynecology and endocrinology, is of great interest thereby resulting to higher adoption.
  • These tests enable the identification of the susceptibility of genes towards postmenopausal osteoporosis, adenomyosis, and endometriosis.
  • Breast and ovarian cancer based predictive testing accounted for the largest share owing to the rising use of susceptibility testing for BRCA mutations cancer prediction.
  • Government and pertinent organizations are engaged in endeavors aimed at curbing cancer-related healthcare expenditure by encouraging patients to undergo regular diagnostic examinations.
  • Key players contributing in this market are BGI, Illumina, Inc, Pathway Genomics, Genesis Genetics, 23andMe, Inc, ARUP Laboratories, Color Genomics Inc., and Myriad Genetics, Inc.
  • These entities are involved in collaborations in order to develop their portfolio with respect to fragmented point-solutions across the genomics value chain.

Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More

Topics

News

ONC Roundup: Senior Leadership Changes Spark Questions

The Office of the National Coordinator for Health IT (ONC) has continued to experience changes within its upper leadership, leading some folks to again ponder what the health IT agency’s role will be moving forward.

Media Report: Walmart Hires Former Humana Executive to Run Health Unit

Reigniting speculation that Walmart and insurer Humana are exploring ways to forge a closer partnership, Walmart Inc. has hired a Humana veteran to run its health care business, according to a report from Bloomberg.

Value-Based Care Shift Has Halted, Study Finds

A new study of 451 physicians and health plan executives suggests that progress toward value-based care has stalled. In fact, it may have even taken a step backward over the past year, the research revealed.

Study: EHRs Tied with Lower Hospital Mortality, But Only After Systems Have Matured

Over the past decade, there has been significant national investment in electronic health record (EHR) systems at U.S. hospitals, which was expected to result in improved quality and efficiency of care. However, evidence linking EHR adoption to better care is mixed, according to medical researchers.

Nursing Notes Can Help Predict ICU Survival, Study Finds

Researchers at the University of Waterloo in Ontario have found that sentiments in healthcare providers’ nursing notes can be good indicators of whether intensive care unit (ICU) patients will survive.

Health Catalyst Completes Acquisition of HIE Technology Company Medicity

Salt Lake City-based Health Catalyst, a data analytics company, has completed its acquisition of Medicity, a developer of health information exchange (HIE) technology, and the deal adds data exchange capabilities to Health Catalyst’s data, analytics and decision support solutions.